Reproductive Technologies, Inc.

CLOSEOUT LETTER Reproductive Technologies, Inc. MARCS-CMS 594292 — December 03, 2021 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UNITED PARCEL SERVICE Reference #: #OBPO 20-594292 Product: Biologics Recipient: Recipient Name Ms. Alice H. Ruby Recipient Title Executive Director Reproductive Technologies, Inc. 2115 Milvia Street Suite 201 Berkeley , CA 94704 United States Issuing Office: Office of Biological Products Operations - Division 2 United States Dear Ms. Ruby: The Food and Drug Administration has completed evaluation of Reproductive Technologies, Inc.’s corrective actions in response to our Warning Letter #OBPO 20-594292 dated November 6, 2019. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Young Mi Yoon Compliance Officer Division 2 Compliance Branch Office of Biological Products Operations (OBPO) Office of Regulatory Affairs U.S. Food and Drug Administration Content current as of: 12/14/2021 Regulated Product(s) Biologics